Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21517
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheung, Yee-Ming-
dc.contributor.authorRamchand, Sabashini K-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorGrossmann, Mathis-
dc.date2019-05-07-
dc.date.accessioned2019-08-12T05:01:11Z-
dc.date.available2019-08-12T05:01:11Z-
dc.date.issued2019-07-01-
dc.identifier.citationJournal of the Endocrine Society 2019; 3(7): 1283-1301-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/21517-
dc.description.abstractEstrogen receptor-positive early breast cancer is common and has a relatively good prognosis. It shares risk factors with cardiovascular disease, and cardiovascular disease is an important competing cause of mortality. Adjuvant endocrine therapy with aromatase inhibitors (requiring concomitant ovarian suppression in premenopausal women) or selective estrogen receptor modulators (usually tamoxifen) exert oncologic benefits by respectively inhibiting estradiol synthesis or breast estrogen receptor signaling. Aromatase inhibitors cause systemic estradiol depletion. Tamoxifen has mixed agonistic/antagonistic effects in a tissue-dependent fashion. Given that estrogens modulate cardiometabolic risk, a review of the effects of endocrine therapy on cardiometabolic outcomes is pertinent. The current, but limited, evidence suggests that tamoxifen treatment, although associated with increases in body fat, hepatic steatosis, serum triglycerides, and diabetes risk, modestly reduces low-density lipoprotein cholesterol and lipoprotein(a) and may have favorable effects on markers of subclinical atherosclerosis. Tamoxifen is associated with either no effect on, or a reduction in, cardiovascular events, and it is associated with an increase in venous thromboembolic events. Aromatase inhibitors, although fewer studies are available and often confounded by comparison with tamoxifen, have not been consistently associated with adverse changes in cardiometabolic risk factors or increases in cardiovascular events. Further clinical trials designed to evaluate cardiometabolic outcomes are needed to more accurately determine the effects of endocrine therapy on cardiovascular risks, to inform individualized decisions regarding choice and duration of endocrine therapy, and to implement evidence-based strategies to mitigate cardiometabolic risks. In the meantime, although breast cancer-specific evidence for benefit of lifestyle measures is available and recommended routinely, proactive monitoring and treatment of cardiovascular risk factors should follow general population recommendations.-
dc.language.isoeng-
dc.subjectaromatase inhibitor-
dc.subjectbreast cancer-
dc.subjectcardiovascular disease-
dc.subjectselective estrogen receptor modulator-
dc.titleCardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer.-
dc.typeJournal Article-
dc.typeReview-
dc.identifier.journaltitleJournal of the Endocrine Society-
dc.identifier.affiliationDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1210/js.2019-00096-
dc.identifier.orcid0000-0002-9218-9917-
dc.identifier.orcid0000-0001-8261-3457-
dc.identifier.pubmedid31259291-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.